FlandersBio on Twitter

Follow us on Twitter

Archive for February 2017 - News

Archive for February 2017 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Atlantic Healthcare confirms alicaforsen targets TLR-9, providing a second mechanism of action to treat new and existing inflammatory indications

28.02.2017

Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, announces that, in addition to targeting ICAM-1, alicaforsen has been shown to target Toll-like receptor 9 (TLR-9). TLR-9 is a recognised target for the treatment of autoimmune diseases including inflammatory bowel disease (IBD). Alicaforsen is currently being evaluated in a pivotal Phase 3 trial for the treatment of pouchitis, a serious form of IBD for which there are limited treatment options. read more

Esperite N.V.: Update on Financing

28.02.2017

Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") confirms that preparations for a significant external funding are still ongoing and Esperite has made good progress in its negotiation with a potential external investor. However, such negotiations have not yet reached the level that Esperite can announce more details. An update about the Group's funding will be communicated by 31 March 2017, or earlier as appropriate. read more

GENTICEL announces its 2016 annual results

28.02.2017

GENTICEL (Euronext Paris and Brussels: FR0011790542) GTCL presents today its 2016 full year results in accordance with International Financial Reporting Standards (IFRS). Genticel’s 2016 Annual Financial Report including the Management Report is available on the company website (www.genticel.com - Investors/Financial information section) in French. An English version will be made available before mid-March. read more

argenx to Present at Cowen & Co 37th Annual Health Care conference

28.02.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer Tim Van Hauwermeiren Chief Executive Officer, will present a company overview at the Cowen & Co. 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place. read more

MITHRA AGREES EXCLUSIVE LONG-TERM LICENSE AND SUPPLY AGREEMENT WITH MAYNE PHARMA TO COMMERCIALIZE MYRING(TM) IN THE US

28.02.2017

Mithra Pharmaceuticals, a company dedicated to Women's Health, is pleased to announce an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization in the United States of Myring(TM), Mithra's combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). Mayne Pharma is the second largest supplier of oral contraceptive products in the US market. read more

argenx announces extension of therapeutic antibody alliance with Shire

28.02.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018. read more

Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451

24.02.2017

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study. read more

Galapagos reports strong financial results and newsflow-rich pipeline

24.02.2017

Galapagos NV (Euronext & NASDAQ: GLPG) presents financial results and highlights the key events for the full year 2016. read more

MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy

23.02.2017

MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed a distribution agreement to make its SelectMDx(TM) for Prostate Cancer test available to Istituto Diagnostico Varelli's urology clients throughout central-south Italy. read more

Biocartis Group NV: Biocartis to host webcast for announcement 2016 financial results on 2 March 2017

23.02.2017

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday, 2 March 2017 at 14:00 CET / 13:00 BST (UK) / 08:00 EDT (US) to announce its 2016 results and 2017 outlook. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print